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Memory impairments may occur due to various reasons. The most often ones include neurodegenerative disorders, for 
instance Alzheimer’s disease (AD). Nowadays, proper pharmacotherapy of this illness is not known, it is only possible 
to attenuate some symptoms of this disease by enhancing cholinergic neurotransmission. Donepezil is an example 
of acetylcholinesterase (AChE) inhibitors used in patients suffering from AD. In the present work using two spatial 
memory tasks, the Morris water maze and the two-day radial-arm water maze, we examined its anti-amnesic efficacy 
in the scopolamine-induced mouse model of memory impairments. Donepezil at a dose of 10 mg/kg b.w. only slightly 
improved cognition in both the assays. Hence, we conclude that the enhancement of cholinergic neurotransmission 
due to selective AChE inhibition may be insufficient to improve cognition in this model, and dual acetylcholinesterase/
butyrylcholinesterase inhibitors seem to be a better option for the attenuation of memory impairments.
Key words: donepezil, acetylocholinesterase, spatial memory, Morris water maze, 
radial-arm water maze
INTRODUCTION
Alzheimer’s Disease (AD) is the most com-
mon cause of dementia in humans (60-70%). 
Furthermore, an increase in prevalence and 
treatment costs of AD are reported nowadays; in 
2013 there were about 44.4 million of patients 
worldwide. The currently used guidelines, accord-
ing to the International Statistical Classification 
of Diseases and Related Health Problems, 10th 
revision (ICD-10, updated in 2015), Diagnostic 
and Statistical Manual of Mental Disorders, 5th 
edition (DSM-V, 2013) and The NINCDS-ADRDA 
Alzheimer’s Criteria (1984, updated in 2007) 
(DUBOIS et al., 2007) distinguish similar diagnostic 
criteria and symptoms of AD, and report impair-
ments in cognitive functions and memory as the 
most frequent ones. Over the years researchers 
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have formulated several hypotheses of AD but its 
real mechanisms have never been fully under-
stood. Current treatments provide only a reduc-
tion in leading symptoms and are based on the 
oldest cholinergic hypothesis according to which 
patient’s cognitive dysfunction is due to deterio-
ration in the cholinergic system action (GIACOBINI, 
1990; GIACOBINI, 2003; HOLZGRABE et al., 2007; 
RAHIM et al., 2015). In the late 1980s and 1990s 
scientists proved the effectiveness of acetylcho-
linesterase inhibitors in several clinical trials 
(DAVIS et al., 1992; FARLOW et al., 1992; KNAPP 
et al., 1994). To date, the U.S. Food and Drugs 
Administration has approved five drugs for the 
therapy of AD. Four of them are acetylcholine-
sterase (AChE) inhibitors: tacrine (withdrawn 
from the market due to its hepatotoxicity), riv-
astigmine, galantamine and donepezil.
Acetylcholinesterase (EC 3.1.1.7) is an enzyme 
involved in acetylcholine (ACh) degradation. 
It belongs to hydrolases and is located in the 
postsynaptic membrane. There are also other 
enzymes, for instance butyrylcholinesterase 
(BChE, EC 3.1.1.8), that metabolize ACh. BChE 
is present not only in the central nervous sys-
tem (MAURICE et al., 2015) but also in plasma and 
liver. The gathered data suggest a beneficial effect 
of BChE inhibitors on cognitive functions, which 
is a novel approach to the treatment of memory 
impairments (FURUKAWA-HIBI et al., 2011; HONG et 
al., 2014; HUANG et al., 2014; REID and DARVESH, 
2015). Thus, to assess the role of AChE in cogni-
tive deficits in experimental animals, the present 
study is focused on the effect of donepezil, an 
AChE inhibitor, on spatial memory and learning 
processes in mice with scopolamine-induced cog-
nitive deficits. Scopolamine is regarded as a “gold 
standard” for inducing memory impairments in 
mice (KLINKENBERG and BLOKLAND, 2011).
MATERIALS AND METHODS
Animals
Male C57BL/6 mice weighing 16-22 g were provid-
ed by the Animal Breeding Farm of the University 
Children’s Hospital of Cracow. The animals were 
kept under standard laboratory conditions: light/
dark cycle (12:12), at room temperature 22±2°C, 
in groups of 10 animals per cage. Food and water 
were available ad libitum. All the procedures 
applied in in vivo experiments were approved by 
the 1st Local Ethics Committee of the Jagiellonian 
University in Cracow (ZI/862/2013).
Chemicals and behavioural testing protocol
Donepezil was purchased from Sigma Aldrich 
(Poland). Before the experiments, it was dissolved 
in 1% solution of Tween 80 (Polskie Odczynniki 
Chemiczne, Poland) and administered intraperito-
neally (ip) at a dose of 10 mg/kg b.w. Scopolamine 
hydrobromide was provided by Sigma Aldrich 
(Poland). To induce memory impairments it was 
dissolved in 0.9% solution of sodium chloride 
(Polpharma, Poland) and administered ip at a dose 
of 1 mg/kg b.w. 
Donepezil was injected once daily, 1 h before 
the first training session. 0.5 h before the first 
swimming trial scopolamine hydrobromide solu-
tion was administered. Two control groups were 
used, i.e. mice receiving either (1) 0.9% saline 1 h 
before the first training or (2) 0.9% saline and 
scopolamine hydrobromide 1 h and 0.5 h before 
the training, respectively.
Morris water maze task 
The Morris water maze task (MWM) was per-
formed according to the method described pre-
viously (PATIL et al., 2009). The apparatus for 
the MWM (Panlab-Harvard Apparatus, Spain) is 
a round pool (diameter: 120 cm, height: 60 cm), 
filled with water (temperature maintained at 
23±1ºC) to such a level that the round platform 
(diameter: 12 cm) is covered with a 0.5 cm layer 
of water. The whole experiment was recorded 
using a computer program (Smart v. 3.0, Panlab-
Harvard Apparatus, Spain); the camera was 
attached to the room wall in such a manner that 
its lens was located above the central point of 
the pool. The pool was virtually divided into four 
equal quadrants, named after compass locations 
(NW, NE, SE and SW).
The test lasted 7 consecutive days and was 
divided into two parts: the acquisition phase 
(days 1–6) and the retention phase (day 7; drug-
off trial). During the first 6 days of the MWM, 
each mouse swam 4 times daily (the maximum 
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time of swimming: 60 s), starting in the NE quad-
rant; the underwater platform was constantly 
located in NW. In this phase the following para-
meters were measured and then analyzed: the 
escape latency time to find the hidden platform 
and the travelled distance to the platform.
The retention phase of the MWM was performed 
on day 7, starting 24 h after the last swimming 
session on the previous day. During the retention 
phase the platform was removed from the pool and 
each mouse was subjected to only one swimming 
trial. No drugs were administered on that day and 
the following parameters were measured: the time 
spent in the target NW quadrant and virtual target 
crossings (i.e., crossings over the place where the 
platform was previously located).
Radial-arm water maze (RAWM)
The two-day RAWM paradigm was introduced 
(ALAMED et al., 2006). An eight-arm maze was inser-
ted into the round pool, the same as that used in 
the MWM task. The platform (diameter: 12 cm, 
height: 30 cm) was located in one of the maze arms.
On the first day of the test (the acquisition 
phase) each mouse swam 15 times (the maxi-
mum time of a single swimming trial: 60 s) start-
ing each time from the constant arm of the maze. 
From session 1 to session 12 the height-adjusta-
ble platform was conversely visible (located slight-
ly above the water surface) or hidden (slightly 
below the water surface), starting from the visible 
mode. During the last three sessions (13–15) the 
platform remained constantly hidden.
On the second day of the RAWM (the reten-
tion phase) the platform was hidden during all 
swimming trials. Mice started swimming from an 
arm which was distinct from that they started 
from on day 1; the starting arms varied for each 
mouse during the consecutive training sessions. 
If a mouse did not find the platform during the 
swimming trial, it was gently guided towards it 
and left there for 15 s, then cautiously dried and 
transferred back to the home cage.
The measured parameter in the RAWM was the 
number of errors made by the animal (entries into 
an arm containing no platform). This parameter 
is considered to be a more sensitive indicator of 
procognitive effect than the escape latency time 
(ALAMED et al., 2006).
Statistical analysis
All the data were analyzed using Graphpad Prism 
software (v. 5, USA). Two-way repeated measures 
analysis of variance (ANOVA) and the Bonferroni 
multiple comparison test were performed. 
Additionally, unpaired Student’s t-test was car-
ried out. In every case P<0.05 was considered sig-
nificant.
RESULTS
MWM – effect on memory acquisition
In all studied groups a gradual decrease in the 
latency time to reach the hidden platform during 
6 consecutive training days was observed (Fig. 1). 
Vehicle-treated mice had the best performance in 
this test. Statistically significant differences in the 
escape latency time were not found between the 
scopolamine plus donepezil-treated group and the 
scopolamine-treated control group. 
Also a reduction in the distance travelled to 
reach the platform was observed during the con-
secutive days of the acquisition phase. Mice in 
the vehicle-treated group achieved better results 
than scopolamine-treated control animals as 
they covered a significantly shorter distance to 
find the platform. No statistically significant dif-
ferences were found between scopolamine plus 
donepezil-treated mice and scopolamine-treated 
control mice (Fig. 2).
Morris water maze – effect on memory retention 
(probe trial on day 7)
Analyzing the time spent in the target NW quad-
rant on day 7, no significant differences between 
the scopolamine plus donepezil-treated group and 
the scopolamine-treated control group were found 
(Fig. 3).
In contrast to the above findings, both vehi-
cle-treated mice and scopolamine plus donepezil-
treated mice made significantly (P<0.05) more vir-
tual target crossings during the retention phase 
of the MWM as compared with the scopolamine-
treated control (Fig. 4).
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Fig. 2. Effect of donepezil on the distance travelled to 
reach the platform during the acquisition phase of the 
MWM. Statistical analysis: two-way repeated measures 
ANOVA followed by the Bonferroni multiple comparison 
test. Statistical signifi cance: ** P<0.01, **** P<0.0001 
(vs. the vehicle-treated group).
Fig. 1. Effect of donepezil on the escape latency time to 
reach the platform during the acquisition phase in the 
MWM. Statistical analysis: two-way repeated measures 
ANOVA, followed by the Bonferroni multiple comparison 
test: * P<0.05; ** P<0.01 (vs. the scopolamine-treated 
control).
Fig. 3. Effect of donepezil on the time spent in the NW 
quadrant on day 7 of the MWM. Statistical analysis: Stu-
dent’s t-test; P>0.05.
Fig. 4. Effect of donepezil on the number of virtual target 
crossings in the MWM task. Statistical analysis: Student’s 
t-test: * P<0.05 (vs. the vehicle-treated control group) and 
# P<0.05 (vs. the scopolamine-treated control group).
Radial-arm water maze 
– effect on memory acquisition (day 1)
During the acquisition phase of the RAWM sig-
nificant differences between the scopolamine plus 
donepezil-treated group and the scopolamine-
treated control group were found during the first 
3 swimming sessions. Then, scopolamine plus 
donepezil-treated mice still made fewer errors, but 
this difference compared with the scopolamine-
treated control group was not significant. Overall, 
a reduction in the number of errors made by the 
mice was noticed in the consecutive swimming 
sessions (Fig. 5).
Radial-arm water maze 
– effect on memory retention (day 2)
On the second day of the RAWM the results were 
more uniform in all three groups. No significant 
differences were noticed; the effect of donepezil on 
memory was found to be negligible (Fig. 6).
DISCUSSION
In the present study donepezil, an AChE inhibi-
tor, has demonstrated a weak effect on spatial 
learning and memory in mice. Such results are 
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rather unexpected bearing in mind that done-
pezil has been widely used in humans suffering 
from AD (TINKLENBERG et al., 2015). On the other 
hand, available literature data indicate that selec-
tive inhibition of AChE might be insufficient to 
achieve a satisfactory anti-amnesic effect, and the 
so-called “dual” AChE and BChE inhibitors are 
thought to be more effective in dementia-related 
disorders (CHENG et al., 2015). Rivastigmine is an 
example of these drugs, already approved for the 
treatment of AD in humans (BONO et al., 2015). 
The results of our unpublished studies using 
MWM and RAWM suggest that rivastigmine has 
a much better impact on cognition than done-
pezil. Other studies also point out a beneficial 
effect of rivastigmine on memory in rodent models 
(BEJAR et al., 1999). 
There are many studies concerning the activ-
ity of donepezil in tests assessing its impact on 
cognition in rodents. GUO et al. (2015) proved its 
be neficial impact (at lower doses than those used 
in the present work: 0.5–2 mg/kg b.w.) on memo-
ry in the MWM and novel object recognition tasks 
in mice; however, contrary to our work, chronic 
administration of donepezil was assessed and 
transgenic mice were used. Donepezil also posi-
tively modulated memory impairments in other 
learning and memory tests (KWON et al., 2014). In 
a rat model of vascular dementia (bilateral com-
mon carotid arteries occlusion, BCCAo) chronic 
administration of donepezil caused a statisti-
cally significant prolongation of the time spent in 
the target quadrant compared with the BCCAo 
control group in the MWM. In another study 
(NAGAKURA et al., 2013) the activity of donepezil 
in Y-maze and MWM tests was compared with 
that of memantine. The AChE inhibitor demon-
strated a weaker effect on working memory than 
the NMDA receptor antagonist in the transgenic 
mouse model of AD. In another study, donepezil 
improved performance in the MWM when admin-
istered concomitantly with selegiline, a monoam-
ine oxidase-B inhibitor (TAKAHATA et al., 2005). 
However, in one study oral administration of 
donepezil (5 mg/kg b.w.) resulted in a reduc-
tion in the escape latency time in mice in the 
MWM after intracerebral injection of streptozocin 
which is another model of memory impairments 
in rodents (SAXENA et al., 2008). A similar effect 
was obtained after oral administration of tacrine 
(5 mg/kg b.w.). In another study in which trans-
genic mice with cognitive deficits were chroni-
cally treated with donepezil, rivastigmine or gal-
antamine (VAN DAM et al., 2005) there were not 
any statistically significant differences in MWM 
results for control and tested groups, except for 
Fig. 5. Effect of donepezil on the number of errors made 
on day 1 of the RAWM (acquisition phase) during 15 con-
secutive trials divided into 5 trial blocks (T1-T3; T4-T6; 
T7-T9; T10-T12 and T13-T15). Statistical analysis: two-
way repeated measures ANOVA, followed by the Bonfer-
roni multiple comparison test. Statistical signifi cance: 
* P<0.05, ** P<0.01 (vs. the vehicle-treated control group), 
## P<0.01 (vs. the scopolamine-treated control group).
Fig. 6. Effect of donepezil on the number of errors made 
on day 2 of the RAWM (retention phase) during 15 con-
secutive trials divided into 5 trial blocks (T1-T3; T4-T6; 
T7-T9; T10-T12 and T13-T15). Statistical analysis: two-
way repeated measures ANOVA followed by the Bonfer-
roni multiple comparison test: P>0.05.
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the travelled distance which was gradually being 
reduced in drug-treated mice. However, VAN DAM 
et al. (2005) used much lower doses of donepezil 
(0.3 or 0.6 mg/kg b.w.) than we did. Donepezil 
did not attenuate scopolamine-induced special 
mapping impairment in rats in a study using 
acute treatment with this drug (2 or 3 mg/kg 
b.w.) in the MWM (LINDER, 2006). 
On the basis on the above data it can be con-
cluded that donepezil influences spatial memory 
in rodent models of cognitive impairments but 
this effect strongly depends on the treatment 
protocol used (acute or chronic), as well as the 
dosage and the type of rodent model of dementia 
applied. It has to be strongly emphasized that the 
reason for this fluctuation still remains unknown. 
As mentioned previously, there is no causal 
therapy for AD. Drugs like donepezil may only 
attenuate symptoms of this disease; hence there 
is a strong need for searching for new compounds 
acting in a different way. To date, there have been 
many promising results of studies assessing the 
activity of BChE inhibitors (FURUKAWA-HIBI et al., 
2011; HUANG et al., 2014). Some studies also 
proved that BChE-knockout mice showed good 
learning capacities and the deposition of amyloid-b 
was reduced (MAURICE et al., 2015; REID and 
DARVESH, 2015). 
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